| Name | Title | Contact Details |
|---|
Vista Pharmaceuticals is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy with 28 years of innovative excellence and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. BioPlus earned a #1 patient satisfaction ranking in both oncology and hepatitis C in Zitter`s Specialty Pharmacy Patient Satisfaction Survey. Our RxExpress program moves each prescription through our system in the most streamline way. From the 2-Hour Patient Acceptance Guarantee at the beginning to the 2-Day Ready 2 Ship at the end, along with free overnight shipping, physicians and patients can trust BioPlus to provide effective service that`s delivered fast. By keeping the wait time for medications as short as possible, patients don`t have to wait to get back to living their lives. BioPlus provides a complete range of specialty services, including for cancer, hepatitis C, multiple sclerosis, rheumatoid arthritis, dermatology, and other complex, chronic conditions. We are a privately-held, pharmacist-owned company based in Altamonte Springs, Florida and accredited by URAC, VIPPS, and ACHC with a Distinction in Oncology.`
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.